Men who are overweight or obese when diagnosed with prostate cancer are at greater risk of death after treatment, according to a new study in the December 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study, by Dr. Jason Efstathiou from Massachusetts General Hospital in Boston and colleagues, found that a greater body mass index (BMI) at the time of cancer diagnosis was an independent risk factor for prostate cancer-related death.
Anticancer drug Nexavar raised survival period in inoperable hepatocellular carcinoma patients suffering from this kind of liver cancer. The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.
High-risk morbidly obese patients who lose 5 to 10 percent of their excess body weight before undergoing gastric bypass surgery appear to have shorter hospital stays and more rapid postoperative weight loss, according to a report in the October issue of Archives of Surgery, a theme issue on bariatric surgery.
Children who lost weight were able to keep it off more effectively by participating in maintenance treatment programs that emphasized behavioral skills or social facilitation, although the effectiveness lessened over time, according to a study in the Oct. 10 issue of JAMA.
There have been improvements in cancer survival in Northern Ireland between 1993 and 2004, according to a new report from the Northern Ireland Cancer Registry (NICR).
Until October_27, 2007, the Federal Trade Commission will be accepting refund requests from consumers who bought CortiSlim or CortiStress. The FTC alleged that CortiSlim was advertised with false and unsubstantiated weight loss claims and that CortiStress was advertised with false and unsubstantiated disease prevention claims.
GlaxoSmithKline (GSK) announced its marketing application for non-prescription orlistat 60mg for weight loss has been accepted for review by the European Agency for the Evaluation of Medicinal Products (EMEA).
The Alternate Healthy Eating Index measures and compares factors in a person’s diet that are strongly linked to reducing risk for cardiovascular disease. According to researchers at the University of Massachusetts who compared the dietary quality of several popular weight-loss plans, none of the plans achieved a perfect AHEI score, “but the Ornish, Weight Watchers high-carbohydrate and New Glucose Revolution plans were among the best performers using the AHEI and traditional dietary quality assessments.”
Amylin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the SymlinPen(TM) 120 and the SymlinPen(TM) 60 pen-injector devices for administering SYMLIN(R) (pramlintide acetate) injection.